Grifols SA (GRFS)

6.405 +0.14 (+2.15%) USD  |  NASDAQ  |  Apr 26, 14:56
More

Grifols Research and Development Expense (Quarterly): 128.58M for Dec. 31, 2023

Research and Development Expense (Quarterly) Chart

Historical Research and Development Expense (Quarterly) Data

View and export this data back to 2011. Upgrade now.
Date Value
December 31, 2023 128.58M
September 30, 2023 95.46M
June 30, 2023 95.22M
December 31, 2022 108.64M
September 30, 2022 94.30M
June 30, 2022 90.67M
June 30, 2021 104.53M
March 31, 2021 86.53M
December 31, 2020 96.28M
September 30, 2020 83.44M
June 30, 2020 81.77M
March 31, 2020 74.89M
December 31, 2019 83.08M
September 30, 2019 76.07M
June 30, 2019 78.60M
March 31, 2019 71.12M
December 31, 2018 80.07M
September 30, 2018 67.71M
June 30, 2018 69.59M
March 31, 2018 66.30M
December 31, 2017 125.34M
September 30, 2017 70.90M
June 30, 2017 68.66M
March 31, 2017 63.03M
Date Value
December 31, 2016 51.74M
September 30, 2016 58.39M
June 30, 2016 56.13M
March 31, 2016 52.58M
December 31, 2015 72.28M
September 30, 2015 60.23M
June 30, 2015 58.59M
March 31, 2015 57.45M
December 31, 2014 66.46M
September 30, 2014 56.12M
June 30, 2014 64.87M
March 31, 2014 51.92M
December 31, 2013 44.94M
September 30, 2013 42.13M
June 30, 2013 38.09M
March 31, 2013 38.69M
December 31, 2012 44.20M
September 30, 2012 39.59M
June 30, 2012 38.99M
March 31, 2012 37.15M
December 31, 2011 41.73M
September 30, 2011 39.89M
June 30, 2011 26.91M
March 31, 2011 15.71M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Quarterly) Range, Past 5 Years

74.89M
Minimum
Mar 2020
128.58M
Maximum
Dec 2023
91.87M
Average
90.67M
Median
Jun 2022

Research and Development Expense (Quarterly) Benchmarks

DBV Technologies SA 12.78M
Adaptimmune Therapeutics PLC 33.21M
Biodexa Pharmaceuticals Plc --
NuCana PLC 8.519M
Autolus Therapeutics PLC 25.16M